Avalo Therapeutics price to book ratio AVTX

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 0.8×
10-year median: 6.0×
Against its 10-year history: 9th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.2× to 81.0×
Peer median: 1.9×

Avalo Therapeutics' price to book ratio is 0.8× as of Oct 23, 2026.

That is below its ten-year median of 6.0×, lower than on 91% of days in the last ten years.

Over that time it ranged from 0.2× in Jan 2024 to 81.0× in Nov 2016.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.8×	0.8×	14.9×
2025	3.6×	0.3×	4.2×
2024	4.1×	0.2×	6.6×
2023	0.5×	0.5×	1.2×
2022	5.3×	2.0×	9.4×
2021	4.7×	4.7×	13.4×
2020	5.1×	3.1×	12.2×
2019	12.4×	6.7×	12.9×
2018	6.6×	3.2×	8.5×
2017	3.8×	1.2×	40.9×
2016	13.9×	2.2×	81.0×

Against its peers

Companies in Drug Manufacturers - General nearest Avalo Therapeutics' size, closest first, today.

Company	Price to book ratio
AVTXAvalo Therapeutics	0.8×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
NATRNatures Sunshine Products	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Avalo Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.